The divestitures streamline Charles River's portfolio toward higher-margin businesses. While revenue will decline, the EPS and margin improvements could be positively received by investors focused on profitability. Monitor closing of transactions in Q2 2026 and subsequent margin performance.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $167.50entry
- T+1 · 9mo ago +4.63%α +5.18% · $175.26
- T+5 · 9mo ago +7.17%α +8.27% · $179.51
- T+20 · 8mo ago −1.56%α +3.68% · $164.89
- T+60 · 6mo ago −6.85%α −13.80% · $156.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Charles River Laboratories announced the planned divestiture of its CDMO and Cell Solutions businesses to GI Partners for contingent payments, and certain European Discovery Services assets to IQVIA for $145 million in cash plus up to $10 million in additional payments. The company updated its 2026 guidance, expecting the transactions to reduce reported revenue by over $200 million but improve non-GAAP EPS by ~$0.10 and add 100 basis points to non-GAAP operating margin.
Key Facts
- Divesting CDMO and Cell Solutions businesses to GI Partners for future contingent payments; combined 2025 revenue of $143 million
- Divesting European Discovery Services assets to IQVIA for $145 million cash plus up to $10 million in additional payments; 2025 revenue of $144 million
- Both transactions expected to close in Q2 2026
- Planned divestitures to reduce 2026 reported revenue by slightly more than $200 million
- Expected to generate at least 100 basis points of incremental non-GAAP operating margin improvement in 2026
- Expected to add approximately $0.10 to non-GAAP EPS for the partial year
Financial Impact
Revenue reduction of >$200 million in 2026, $0.10 accretion to non-GAAP EPS, 100 bps improvement in non-GAAP operating margin
Risk Factors
- Failure to complete either divestiture transaction as planned
- Potential for higher-than-expected divestiture-related costs that could reduce the non-GAAP EPS benefit
- Loss of revenue streams could impact growth metrics despite margin improvements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-011395 |
| Document: 0001628280-26-011395-index-headers.html | 0001628280-26-011395 |
| Document: 0001628280-26-011395-index.html | 0001628280-26-011395 |
| Document: 0001628280-26-011395.txt | 0001628280-26-011395 |
Track record
17 reports on CRL
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +44.25% at T+60 after the Aug 5, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $333.18 Now $335.52 +0.70% settles Dec 15
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $345.80 Now $335.52 −2.97% settles Dec 9
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $353.34 Now $335.52 −5.04% settles Dec 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $313.02 Now $335.52 +7.19% settles Dec 4
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $326.29 Now $335.52 +2.83% settles Dec 3
- Oct 26, 202621d ago Insider Cluster Neutral 2/10 Entry $358.84 Now $335.52 −6.50% settles Nov 24
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $345.37 Now $335.52 −2.85% settles Nov 20
- Oct 21, 202626d ago Institutional Cluster Bullish 4/10 Entry $339.66 Now $335.52 −1.22% settles Nov 19
- Sep 24, 20267w ago 8-K Bullish 6/10 Entry $294.44 to $339.66 Now $335.52 +13.95% ▲ +15.36% +15.78% vs SPY
- Aug 27, 202611w ago Insider Cluster Neutral 3/10 Entry $291.50 to $294.59 Now $335.52 +15.10% ▲ +1.06% +1.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers